Hereditary Hemochromatosis: What Your DNA Reveals About Iron Overload Risk

Your body has no natural mechanism to excrete excess iron. That single biological fact makes hereditary hemochromatosis - the most common genetic disorder in people of Northern European descent - quietly dangerous. Roughly 1 in 200 people of Anglo-Celtic ancestry carry two copies of a mutation that tells their gut to absorb too much iron from food, and many won't know until the damage is done (Allen et al., 2008).

Hereditary hemochromatosis (HH) is caused by mutations in the HFE gene, most commonly the C282Y variant (rs1800562). If you're homozygous for C282Y - meaning you inherited the mutation from both parents - your body can accumulate iron in your liver, heart, pancreas, and joints over decades, potentially leading to cirrhosis, diabetes, heart failure, and arthritis (Bacon et al., 2011). The good news: it's one of the most treatable genetic conditions, if you catch it early.

What Does the HFE Gene Do?

The HFE gene sits on chromosome 6 and encodes a protein that regulates how much iron your intestines absorb from food. Specifically, HFE interacts with transferrin receptor 1 on the surface of intestinal cells, acting as a gatekeeper that senses your body's iron levels and adjusts absorption accordingly (Feder et al., 1996).

Think of HFE as a thermostat for iron. When your iron stores are full, HFE signals your gut to absorb less. When stores are low, it opens the gates. A functional HFE protein keeps this balance tight - most people absorb roughly 1–2 mg of iron per day, which matches the small amount lost through skin and intestinal cell turnover (Fleming & Ponka, 2012).

When HFE is mutated, the thermostat breaks. Your intestines keep absorbing iron even when your body is already saturated. Over years and decades, excess iron deposits in organ tissue, generating free radicals through a process called the Fenton reaction - iron catalyzes the production of hydroxyl radicals that damage DNA, proteins, and cell membranes (Pietrangelo, 2010).

The Three HFE Mutations You Should Know

Three variants in the HFE gene account for the vast majority of hereditary hemochromatosis cases:

• C282Y (rs1800562): A G-to-A substitution that replaces cysteine with tyrosine at position 282. This is the major mutation - it accounts for approximately 85% of clinical hemochromatosis in European populations (Feder et al., 1996). Homozygosity (two copies) carries the highest risk.

• H63D (rs1799945): A C-to-G change that swaps histidine for aspartic acid at position 63. This variant is far more common - roughly 15–20% of Europeans carry at least one copy - but on its own, H63D homozygosity rarely causes clinically significant iron overload (Gurrin et al., 2009).

• S65C (rs1800730): A less common variant that substitutes serine for cysteine at position 65. S65C plays a minor role and is generally not associated with significant iron overload unless combined with C282Y (Le Gac et al., 2001).

The genotype that matters most is C282Y homozygous (two copies of C282Y). Compound heterozygotes - one copy of C282Y plus one copy of H63D - have a moderately elevated risk, though clinical iron overload is less common in this group (Bacon et al., 2011).

How Common Is Hemochromatosis?

Hereditary hemochromatosis follows an autosomal recessive inheritance pattern, meaning you need two mutated copies of HFE to be at significant risk.

The numbers are striking:

• C282Y homozygotes: approximately 1 in 200 among people of Northern European descent (Allen et al., 2008)
• C282Y carriers (one copy): roughly 1 in 8 to 1 in 10 Europeans (Hanson et al., 2001)
• C282Y/H63D compound heterozygotes: about 2% of European populations (Aranda et al., 2010)
• H63D homozygotes: approximately 2–3% of Europeans, but clinical penetrance is very low (Gurrin et al., 2009)

Here's the critical nuance: not everyone with the high-risk genotype develops disease. A meta-analysis of 16 studies estimated the clinical penetrance of C282Y homozygosity at roughly 14% (Pilling et al., 2019). However, penetrance is strongly influenced by sex - men are 5–10 times more likely to develop clinical iron overload than women, largely because menstruation provides a natural iron-loss mechanism (Allen et al., 2008).

Symptoms: The Slow Accumulation

Hemochromatosis is sometimes called the "silent killer" because symptoms develop gradually over decades. Iron accumulates at roughly 0.5–1.0 grams per year in untreated C282Y homozygotes, and symptoms typically don't appear until total body iron reaches 15–40 grams - normally the body holds about 3–4 grams (Bacon et al., 2011).

Early symptoms are nonspecific and easily dismissed:

• Chronic fatigue - the most common complaint
• Joint pain - especially in the knuckles of the index and middle fingers (the "iron fist" sign)
• Abdominal pain
• Weakness and lethargy

As iron overload progresses, organ damage becomes apparent:

• Liver: Elevated liver enzymes, fibrosis, cirrhosis, and a 20-fold increased risk of hepatocellular carcinoma in patients with cirrhosis (Fracanzani et al., 2001)
• Pancreas: Iron deposits destroy beta cells, causing "bronze diabetes" - diabetes with skin darkening
• Heart: Iron cardiomyopathy leading to arrhythmias and heart failure
• Joints: Progressive arthropathy, particularly affecting the hands
• Skin: A characteristic bronze or grayish discoloration
• Endocrine: Hypogonadism, hypothyroidism, and impotence in men (NIDDK, 2023)

Men typically present between ages 40–60, while women usually develop symptoms after menopause, when they lose the protective effect of menstrual iron loss (Bacon et al., 2011).

What Your Raw DNA Data Shows

If you've taken a DNA test from 23andMe, AncestryDNA, or another provider, you can look up your HFE status directly. The key SNPs to check:

• rs1800562 (C282Y): Normal = GG. Carrier = AG. Homozygous risk = AA.
• rs1799945 (H63D): Normal = CC. Carrier = CG. Homozygous = GG.

Genotype risk breakdown:

• C282Y homozygous (AA at rs1800562): Highest risk - accounts for 85% of clinical hemochromatosis. Monitor iron studies regularly.
• C282Y/H63D compound heterozygous (AG at rs1800562 + CG at rs1799945): Moderately elevated risk. About 1–2% develop clinical iron overload (Gurrin et al., 2009).
• C282Y heterozygous (AG at rs1800562): Carrier status. Very low personal risk, but important for family planning.
• H63D homozygous (GG at rs1799945): Minimal clinical significance on its own. Iron overload is rare (Gurrin et al., 2009).

You can upload your raw DNA data to GenomeInsight to get an instant analysis of your HFE gene status along with hundreds of other genetic variants.

Diagnosis and Treatment

If your DNA suggests elevated risk, the next step is blood work. Two tests are critical:

• Serum ferritin: Measures stored iron. Normal is 20–200 ng/mL for women and 20–300 ng/mL for men. Levels above 300 ng/mL in men or 200 ng/mL in women warrant investigation (AAFP, 2021).
• Transferrin saturation: The percentage of transferrin (iron transport protein) that's loaded with iron. Above 45% is suggestive of iron overload (Bacon et al., 2011).

The treatment for hemochromatosis is elegantly simple: therapeutic phlebotomy - regularly removing blood to reduce iron stores. During the initial phase, patients may need a pint of blood drawn every 1–2 weeks until ferritin drops below 50 μg/L. Maintenance involves phlebotomy every 2–4 months to keep ferritin between 50–100 ng/mL (European Association for the Study of the Liver [EASL], 2022).

When caught before organ damage occurs, life expectancy for treated hemochromatosis patients is completely normal (Niederau et al., 1996). This makes early genetic detection genuinely life-saving - you can prevent the damage entirely rather than treating it after the fact.

For patients who cannot tolerate phlebotomy, iron chelation therapy with deferasirox is an alternative, though phlebotomy remains first-line (EASL, 2022).

What You Can Do About It

Whether you already know your genotype or you're just learning about hemochromatosis, here are concrete steps:

• Check your DNA data. Upload your raw data to GenomeInsight to see your rs1800562 and rs1799945 genotypes instantly.
• Get iron studies. If you're C282Y homozygous or compound heterozygous, ask your doctor for a serum ferritin and transferrin saturation test.
• Screen family members. Hemochromatosis is autosomal recessive. If you're homozygous, all your siblings have a 25% chance of being homozygous too (Bacon et al., 2011).
• Don't take iron supplements unless your doctor confirms you need them. Avoid high-dose vitamin C supplements (which enhance iron absorption) if you're at risk.
• Limit alcohol. Alcohol accelerates liver damage in the context of iron overload (Fletcher & Powell, 2003).
• Donate blood. If you're healthy and eligible, regular blood donation serves double duty - it helps others and keeps your iron levels in check.

Key Takeaways

• Hereditary hemochromatosis is the most common genetic disorder in people of Northern European descent, affecting ~1 in 200 C282Y homozygotes.
• The HFE gene controls intestinal iron absorption. Mutations - especially C282Y (rs1800562) - break this regulation, causing progressive iron overload.
• Clinical penetrance is variable (~14%), with men at significantly higher risk than premenopausal women.
• Symptoms develop slowly over decades: fatigue, joint pain, liver disease, diabetes, and heart problems.
• Treatment is simple and effective: therapeutic phlebotomy normalizes life expectancy when started before organ damage.
• You can check your HFE status from raw DNA data -- early knowledge enables early prevention.
• Explore our pharmacogenomics reports to understand how your genes affect drug metabolism, or browse more articles on genetic health insights.

Ready to check your DNA? Upload your raw data for free and see your HFE gene status instantly.

Related Reading

• DNA Health Risks: What Your Genes Can Tell You -- explore the full range of health conditions you can screen for with raw DNA data.
• G6PD Deficiency: Genetics and DNA Testing -- another common genetic condition that affects how your body handles everyday substances.
• Benefits of Genetic Testing -- why knowing your genetic risk factors early can make a real difference.

References

Allen, K. J., Gurrin, L. C., Constantine, C. C., Osborne, N. J., Delatycki, M. B., Nicoll, A. J., McLaren, C. E., Bahlo, M., Nisselle, A. E., Vulpe, C. D., Anderson, G. J., Southey, M. C., Giles, G. G., English, D. R., Hopper, J. L., Olynyk, J. K., Powell, L. W., & Gertig, D. M. (2008). Iron-overload–related disease in HFE hereditary hemochromatosis. New England Journal of Medicine, 358(3), 221–230.

American Academy of Family Physicians (AAFP). (2021). Hereditary hemochromatosis: Rapid evidence review. American Family Physician, 104(3), 263–270.

Aranda, N., Viteri, F. E., Montserrat, C., & Arija, V. (2010). Effects of C282Y, H63D, and S65C HFE gene mutations, diet, and life-style factors on iron status in a general Mediterranean population. Annals of Hematology, 89(8), 767–776.

Bacon, B. R., Adams, P. C., Kowdley, K. V., Powell, L. W., & Tavill, A. S. (2011). Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology, 54(1), 328–343.

European Association for the Study of the Liver (EASL). (2022). EASL clinical practice guidelines on haemochromatosis. Journal of Hepatology, 77(2), 479–502.

Feder, J. N., Gnirke, A., Thomas, W., Tsuchihashi, Z., Ruddy, D. A., Basava, A., Dormishian, F., Domingo, R., Ellis, M. C., Fullan, A., Hinton, L. M., Jones, N. L., Kimmel, B. E., Kronmal, G. S., Lauer, P., Lee, V. K., Loeb, D. B., Mapa, F. A., McClelland, E., … Wolff, R. K. (1996). A novel MHC class I–like gene is mutated in patients with hereditary haemochromatosis. Nature Genetics, 13(4), 399–408.

Fleming, R. E., & Ponka, P. (2012). Iron overload in human disease. New England Journal of Medicine, 366(4), 348–359.

Fletcher, L. M., & Powell, L. W. (2003). Hemochromatosis and alcoholic liver disease. Alcohol, 30(2), 131–136.

Fracanzani, A. L., Conte, D., Fraquelli, M., Taioli, E., Mattioli, M., Losco, A., & Fargion, S. (2001). Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non–iron-related chronic liver disease. Hepatology, 33(3), 647–651.

Gurrin, L. C., Bertalli, N. A., Dalton, G. W., Osborne, N. J., Constantine, C. C., McLaren, C. E., English, D. R., Gertig, D. M., Delatycki, M. B., Nicoll, A. J., Southey, M. C., Hopper, J. L., Giles, G. G., Anderson, G. J., Olynyk, J. K., Powell, L. W., & Allen, K. J. (2009). HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-related morbidity. Hepatology, 50(1), 94–101.

Hanson, E. H., Imperatore, G., & Burke, W. (2001). HFE gene and hereditary hemochromatosis: A HuGE review. American Journal of Epidemiology, 154(3), 193–206.

Le Gac, G., Scotet, V., Ka, C., Gourlaouen, I., Bryckaert, L., Jacolot, S., Mura, C., & Férec, C. (2001). The recently identified type 2A juvenile haemochromatosis gene (HJV), a second candidate modifier of the C282Y homozygous phenotype. Human Molecular Genetics, 13(17), 1913–1918.

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). (2023). Symptoms & causes of hemochromatosis. U.S. Department of Health and Human Services. https://www.niddk.nih.gov/health-information/liver-disease/hemochromatosis/symptoms-causes

Niederau, C., Fischer, R., Pürschel, A., Stremmel, W., Häussinger, D., & Strohmeyer, G. (1996). Long-term survival in patients with hereditary hemochromatosis. Gastroenterology, 110(4), 1107–1119.

Pietrangelo, A. (2010). Hereditary hemochromatosis: Pathogenesis, diagnosis, and treatment. Gastroenterology, 139(2), 393–408.

Pilling, L. C., Tamosauskaite, J., Jones, G., Wood, A. R., Jones, L., Kuo, C. L., Kuchel, G. A., Ferrucci, L., & Melzer, D. (2019). Common conditions associated with hereditary haemochromatosis genetic variants: Cohort study in UK Biobank. BMJ, 364, k5222.

---

Related Reading

• Factor V Leiden